All Tools
Six public-data intelligence modules for pharma, biotech, diagnostics, BD, and investment teams.
Each module answers a specific high-value question using structured public data, entity normalization, evidence-linked scoring, and conservative interpretation. Start with the flagship module or browse by category below.
Clinical Program Risk Radar
Current edition: Oncology Phase 2 Small/Mid-Cap Sponsor Edition
Track public delay, stagnation, termination, recruitment burden, and missing-results signals across clinical assets using ClinicalTrials.gov registry text and snapshot history.
Core question: Which oncology Phase 2 assets or sponsors show public risk signals worth closer review?
Generic Entry Radar
Screen U.S. small-molecule drugs for near-term loss-of-exclusivity windows. Scored by expiry attractiveness, patent complexity, and clinical competition signal.
Core question: Which approved drugs may become commercially interesting as exclusivity changes?
ADC Target Strategy Radar
Current edition: Oncology Edition
Map oncology ADC targets by clinical crowding, clinical maturity, sponsor competition, patent-density signals, recent momentum, and conservative strategy labels.
Core question: Which ADC targets are clinically crowded versus still emerging?
Translational Deal Radar
Current edition: Cell Therapy
Screen translational therapeutic programs for clinical momentum, conservative IP-linkage signals, and BD relevance before deeper diligence begins.
Core question: Which early clinical assets may be worth licensing, investing in, or monitoring?
Protocol Benchmark Radar
Current edition: Lupus Nephritis
Benchmark public trial designs by endpoint precedent, eligibility burden, biomarker strategy, background therapy, and operational risk.
Core question: How does a protocol compare with recent public trial precedent?
Biomarker Patient-Selection Radar
Current edition: Solid Tumor Oncology
Track how oncology biomarkers are used for patient selection, stratification, and treatment assignment in interventional trials, with FDA CDx context and diagnostic patent-density signals.
Core question: Which biomarkers are becoming clinically actionable and commercially important?
Get updates on tools that match your work
Select the modules relevant to your team. We'll send tool updates, new edition launches, and CSV availability notices.